Idt Biologika
Idt Biologika, a prominent player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across Europe and Asia. Founded in 1991, the company has established itself as a leader in the development and manufacturing of vaccines, biologics, and sterile injectables. Idt Biologika is renowned for its innovative approach to contract development and manufacturing, offering unique solutions that cater to the specific needs of its clients. The company’s state-of-the-art facilities and commitment to quality have positioned it as a trusted partner in the global market. With a focus on advancing public health, Idt Biologika has achieved significant milestones, including collaborations with major pharmaceutical companies and contributions to vaccine development. Its dedication to excellence and innovation continues to drive its success in the competitive biopharmaceutical landscape.
DitchCarbon Score
How does Idt Biologika's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Idt Biologika's score of 41 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Idt Biologika's reported carbon emissions
In 2023, IDT Biologika reported total carbon emissions of approximately 8,419,330 kg CO2e for Scope 1 and about 7,209,210 kg CO2e for Scope 2. This reflects a slight decrease in Scope 1 emissions from 2022, which were about 8,443,450 kg CO2e, while Scope 2 emissions decreased from approximately 12,228,900 kg CO2e in the same year. IDT Biologika has set ambitious near-term reduction targets, aiming to decrease its CO2e emissions by 3% annually for both Scope 1 and Scope 2 during 2023 and 2024. Additionally, the company is committed to achieving net-zero emissions across all scopes by 2050, aligning with industry standards and climate commitments. These initiatives demonstrate IDT Biologika's proactive approach to mitigating its environmental impact within the pharmaceuticals, biotechnology, and life sciences sector. The company is currently on track to meet its near-term reduction goals, reinforcing its commitment to sustainability and climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 8,443,450 | 0,000,000 | 0,000,000 |
| Scope 2 | 12,228,900 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Idt Biologika is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
